Nasal Periostin Levels and Acute Symptoms in Asthmatics during Viral-induced Exacerbations

Pham, Sarah; Hardin, Olga; Dinwiddie, Darrell L.; Bhattacharyya, Sudeepa; Stoner, Ashley; Kincaid, John C.; Kirkpatrick, Catherine; Putt, Claire; Kennedy, Joshua L.

doi:10.1016/j.jaci.2018.12.629

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are only isolated reports on the measurement of periostin in nasal secretions of patients with atopic asthma and nasal symptoms. We found a study by Pham et al [ 36 ], which demonstrated abnormally high levels of nasal periostin in patients with asthma that increased even more with asthma exacerbation. In those cases when BA and AR were combined, the levels of nasal periostin were significantly higher than in patients with asthma alone (520.19 and 4.71 pg/ml, respectively; p<0.05).…”

Section: Introductionmentioning

confidence: 55%

“…Lopez-Guisa et al [ 44 ] demonstrated that the expression of periostin genes by nasal epithelial cells after stimulation with IL-4/IL-13 was significantly (3.9-fold) higher in BA patients as compared with non-asthmatics. In a study by Pham et al [ 36 ], abnormally high levels of nasal periostin were found in patients with asthma, and a further increase in periostin was noted during asthma exacerbation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Periostin as a Biomarker of Allergic Inflammation in Atopic Bronchial Asthma and Allergic Rhinitis (a Pilot Study)

Krasilnikova¹,

Tush²,

Frolov³

et al. 2020

Sovrem Tehnol Med

View full text Add to dashboard Cite

The involvement of periostin in Th2-dependent allergic inflammation has been documented. However, the significance of periostin as a biomarker of local allergic inflammation in the nasal mucosa (NM) of patients with atopic bronchial asthma (BA) and allergic rhinitis (AR) is yet to be determined. The aim of the study was to determine the presence of periostin and evaluate its role as a non-invasive marker of allergic inflammation in the nasal secretions of children with atopic BA and AR. Materials and Methods. In 43 patients aged 4–17 years with atopic BA and AR, the NM was examined using nasal video-endoscopy and (if indicated) computed tomography; the amount of periostin in the nasal secretion was determined by the enzyme immunoassay. Results. Exacerbation of AR was accompanied by a statistically significant increase in the level of periostin in the nasal secretion: up to 0.84 [0.06; 48.79] ng/mg, whereas in remission, that was 0.13 [0.00; 0.36] ng/mg; p=0.04. This value increased progressively as the severity of AR increased from 0.16 [0.00; 0.36] ng/mg in the mild course to 0.20 [0.00; 9.03] ng/mg in AR of moderate severity, and to 10.70 [0.56; 769.20] ng/mg in most severe cases; p=0.048. Hypertrophy or polyposis of the nasal and/or paranasal mucosa was detected in 34.9% (15/43) of the examined patients. The concentration of periostin in the nasal secretion was lower in children without NM hypertrophy: 0.18 [0.001; 4.30] ng/mg vs 0.78 [0.13; 162.10] ng/mg in patients with NM hypertrophy; the differences were close to statistically significant: p=0.051. The level of nasal periostin depended on the clinical form of hypertrophy in the sinonasal mucosa, reaching 0.17 [0.00; 0.32] ng/mg in children with polyposis hyperplasia of NM and 21.6 [10.70; 1516.80] ng/mg — with hypertrophy of the NM in the medial surface of the concha; p=0.02. Conclusion. Exacerbation and increased severity of AR in patients with atopic BA are accompanied by an increased level of periostin in the nasal secretion. This allows us to consider the level of nasal periostin as a biomarker of local allergic inflammation in the NM of patients with atopic BA combined with AR. Hypertrophic changes in the sinonasal mucosa are generally accompanied by an increased level of nasal periostin; specifically, this level significantly depends on the clinical form of mucous membrane hypertrophy and requires additional studies.

show abstract

Section: Introductionmentioning

confidence: 55%

Section: Discussionmentioning

confidence: 99%